



Express Mail Mailing Label No. EV457083272US

PATENT
Attorney Docket No. MTP-024

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Watkins *et al.*
SERIAL NO.: 09/709,947 GROUP NO.: 1642
FILING DATE: November 10, 2000 EXAMINER: Harris, Alana M.
TITLE: Materials and Methods for Detection and Treatment of Breast Cancer

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS


In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,




Brian Fairchild, Ph.D.
Attorney for Applicant(s)
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: December 14, 2004
Reg. No. 48,645

Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

3155831_1



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: MTP-024 APPLICANT(S): Watkins et al. SERIAL NO.: 09/709,947 FILING DATE: November 10, 2000 GROUP: 1642					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	C1	Bringmann <i>et al.</i> , (1983) "5'-Terminal Caps of snRNAs Are Accessible for Reaction with 2,2,7-Trimethylguanosine-specific Antibody in Intact snRNPs*," <u>J. Biol. Chem.</u> , 258(5): 2745-2747.							
	C2	Brown <i>et al.</i> , (2001) "Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer," <u>Breast Cancer Res.</u> , 3(5): 323-327.							
	C3	Casciola-Rosen <i>et al.</i> , (1994) "Autoantigens Targeted in Systemic Lupus Erythematosus Are Clustered in Two Populations of Surface structures on Apoptotic Keratinocytes," <u>J. Exp. Med.</u> , 179: 1317-1330.							
	C4	Craft <i>et al.</i> , (1988) "The U2 Small Nuclear Ribonucleoprotein Particle as an Autoantigen: Analysis with Sera from Patients with Overlap Syndromes," <u>J. Clin. Invest.</u> , 81: 1716-1724.							
	C5	El-Hefnawy <i>et al.</i> , (2004) "Characterization of Amplifiable, Circulating RNA in Plasma and its Potential as a Tool for Cancer Diagnostics," <u>Clin. Chem.</u> , 50(3): 564-573.							
	C6	Ochs <i>et al.</i> , (1994) "Coiled bodies in the nucleolus of breast cancer cells," <u>J. Cell Sci.</u> , 107: 385-399.							
	C7	Utz, <i>et al.</i> , (2000) "Death, autoantigen modifications, and tolerance," <u>Arthritis Res.</u> , 2:101-114.							
	C8	Will <i>et al.</i> , (2002) "Characterization of novel SF3B and 17S U2 snRNP proteins, including a human Prp5p homologue and SF3b DEAD-box protein," <u>EMBO J.</u> , 21: 4978-4988.							
EXAMINER					DATE CONSIDERED				